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The clinical outcomes of dendritic cell (DC)–
based immunotherapy remain disappoint-
ing, with DCs often displaying a tenuous
capacity to complete maturation and DC1
polarization in the tumor host. Surprisingly,
we observed that the capacity for success-
ful DC1 polarization, including robust
IL12p70 production, could be regulated by
STAT-dependent events even prior to DC
differentiation. Exposure of CD34pos cells
to single-agent granulocyte-macrophage
colony-stimulating factor (GMCSF) induced
multilineage, STAT5-dependent differentia-
tion, including DCs that failed to mature in
the absence of further exogenous signals.
In contrast, Flt3L induced nearly global dif-
ferentiation of CD34pos cells into spontane-
ously maturing DCs. IL-6 synergized with
Flt3L to produce explosive, STAT3-
dependent proliferation of phenotypically
undifferentiated cells that nevertheless func-
tioned as committed DC1 precursors. Such
precursors not only resisted many tumor-
associated immunosuppressants, but also
responded to tumor contact or TGF with
facilitated DC maturation and IL12p70 pro-
duction, and displayed a superior capacity
to reverse tumor-induced T-cell tolerance.
GMCSF preempted Flt3L or Flt3L plus IL-6
licensing by blocking STAT3 activation and
promoting STAT5-dependent differentiation.
Paradoxically, following overt DC differentia-
tion, STAT5 enhanced whereas STAT3 inhib-
itedDC1polarization.Therefore,nonoverlap-
ping, sequential activation of STAT3 and
STAT5, achievable by sequenced exposure
to Flt3L plus IL-6, then GMCSF, selects for
multilog expansion, programming, and DC1
polarization of tumor-competent DCs from
CD34pos cells. (Blood. 2008;112:1832-1843)
Introduction
Dendritic cells (DCs) are the most potent antigen-presenting cells
in the body and are used in many tumor vaccine immunotherapy
trials, rarely with therapeutic impacts.1,2 DC preparations display
a wide range of characteristics in vitro and in vivo, and it
remains uncertain which individual properties may best promote
successful immunotherapy.3-6
A variety of single agents, including CD40 ligand, Toll-like
receptor (TLR) agonists, and calcium ionophore, can induce DC
phenotypic maturation.3,4,6-9 Such maturation includes pro-
nounced expression of MHC and costimulatory molecules,
CD40 and CCR7, and IL-8 secretion, but falls short of the DC’s
potential to achieve DC1 polarization, a highly effective state
for promoting cell-mediated immunity.4,6,7,9,10 DC1 polarization
includes abundant production of IL12p70 heterodimer and
IL-23, secretion of the chemokine MIP-1, and preferential
expression of Delta-4 Notch ligand.4,6,7 Such DC1 products are
highly associated with chemoattraction and activation of T1-
type CD4 and CD8 T cells.4,6,7 Furthermore, IL12p70 produc-
tion is critical to sensitize high-avidity T cells that directly
recognize and kill tumor targets.4,6,7
Although desirable for antitumor immunity, DC1 polariza-
tion is more easily signaled by infectious agents than by tumor
exposure. Immature DCs use recognition of pathogen-
associated molecular patterns to assess the likelihood of host
infection and the appropriateness of DC1 polarization.6,7 Indi-
vidual TLRs signal DCs primarily through the MyD88 pathway
(eg, TLR7-9) or TRIF pathway (eg, TLR3), with TLR4 evidenc-
ing pathway duplicity.7 Although activation of either pathway
can induce elements of phenotypic DC maturation, dual path-
way activation, or single pathway activation potentiated by
exposure to IFN- or CD40 ligation, is required for robust
DC1 polarization.6,7
Fresh mobilization of DC1 precursors has the theoretic potential
to promote cross-presentation of tumor Ags within the tumor host.
Recent studies confirm the capacity of stem cell–mobilizing
treatments, notably granulocyte-macrophage colony-stimulating
factor (GMCSF), granulocyte colony-stimulating factor, fms-like
tyrosine kinase receptor-3 (Flt3 ligand, Flt3L), or combined Flt3L
plus GMCSF to mobilize DC precursors,5,11-13 but the potential of
such precursors to achieve DC1 polarization is presently unclear.
Flt3L plus GMCSF mobilization was recently reported to induce
abundant infiltration of DCs into mouse tumors, but such DCs also
activated regulatory T cells and promoted tumor tolerance.5
Immunosuppressive factors including IL-10, transforming growth
factor beta (TGF-), vascular endothelial growth factor (VEGF)
and prostaglandin E2 (PGE2) are often produced by tumors, and
Submitted December 19, 2007; accepted May 22, 2008. Prepublished online as
Blood First Edition paper, June 24, 2008; DOI 10.1182/blood-2007-12-130138.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.




 http://ashpublications.org/blood/article-pdf/112/5/1832/1485286/zh801708001832.pdf by guest on 04 D
ecem
ber 2020
may impede mobilized DC precursors from attaining optimal
maturation and DC1 polarization.14-17 However, mobilizing treat-
ments themselves can also influence the later differentiation
responses of stem cells.5,11-13 We therefore postulated that particular
stem cell proliferative treatments might provide conditioning
signals that licensed rather than limited responsiveness to DC1
polarization stimuli.
Stem cell proliferation is inducible via multiple signaling
pathways, including receptor-linked tyrosine kinases (Flt3L and
stem cell factor [SCF]),18-20 gp130 (eg, IL-6),18,19 and the hemato-
poietin receptor superfamily (eg, GMCSF),20 During the systematic
testing of such signaling agents we identified that combined
exposure to Flt3L plus IL-6 (Flt3L  IL-6) not only synergized for
stem cell proliferation, but also licensed CD34pos progenitor cells to
forego multilineage differentiation in favor of STAT3-dependent,
dedicated DC differentiation. Such STAT3-dependent DC differen-
tiation proved highly conducive to DC1-type functional compe-
tence during later interactions with tumor. In contrast, exposure of
CD34pos cells to GMCSF dominantly promoted an alternative,
STAT5-dependent pathway of DC differentiation that was less
conducive to tumor interactions.
Methods
Mice and tumors
All experiments were performed under institutionally approved animal
research committee protocols adhering to USDA guidelines. Female
C57BL/6N, C3H/HeJ, and BALB/c mice were purchased from Biologic
Testing Branch, National Cancer Institute (NCI, Frederick, MD). They were
maintained pathogen-free under UDSA guidelines and studied at 8 to
12 weeks or as indicated. MCA-203, -105, and -205 fibrosarcomas and B16
melanoma, syngeneic to C57BL/6N mice; CT26 colonic adenocarcinoma,
syngeneic to BALB/c mice; and the 888 mel human melanoma line were
maintained as described previously.21,22
After extensive C57BL/6N backcross, STAT5a/b knockout (KO) mice23
with hypomorphic STAT5 expression (N-terminal truncation24) were ob-
tained by breeding heterozygotes to yield viable STAT5ab/ pups. Mice
were genotyped by polymerase chain reaction (PCR) of tail clip genomic
DNA using primer pairs specific for STAT5a and/or STAT5b genes as
previously described.25
Following exhaustive C57BL/6N backcross, mice homozygous for a
STAT3 allele with loxP sequences flanking critical exons 18 to 20 (F allele)
were bred with Tie2-Cre mice (C allele) to generate mice with bone marrow
(BM) conditionally knocked out for STAT3 (STAT3-CFF).26 Tail clip PCR
genotyping distinguished a 490-bp product of wild-type STAT3 from the
520-bp STAT-F product, as well as the presence or absence of a Tie2-Cre
300-bp product.
Reagents
rhFlt3L (gift ofAmgen, Thousand Oaks, CA); rhIL-2 (gift of Chiron, Emeryville,
CA); rmGMCSF (gift of Immunex, Seattle, WA); rmCSF, rmIL-6, rmIL-10,
rmVEGF, rmIL-3, rm thrombopoietin, rmIL-4, rmIFN-, rrhIL-7, and rhIL-15
(Peprotech, Rocky Hill, NJ); rhTGF1 (R&D, Minneapolis, MN); PGE2, LPS
(Escherichia coli 026:B6), poly I:C, and prostaglandin E2 (Sigma-Aldrich, St
Louis, MO); CpG (ODN 1826); and imiquimod (Invivogen, San Diego, CA)
were used. Culture medium (CM) consisted of RPMI-1640 with 10% heat-
deactivated FCS and conventional additives.21
BM proliferation (step 1 of culture)
Mouse BM suspensions were prepared from femurs and tibias.27
Following red blood cell (RBC) lysis by ammonium chloride, 12 to
15 million BM cells (CD34pos cell frequency 8%-12%) were cultured at
0.5 million/mL in 75-cm2 flasks (Corning, Corning, NY) at 10% CO2 in
CM with the factors to be tested: hFlt3L 25 ng/mL (similar results
25-300 ng/mL); mIL-6 25 ng/mL (similar results 25-100 ng/mL;
100 ng/mL rhIL-6 also effective); mSCF 25 ng/mL (similar results
25-100 ng/mL; rSCF also effective); rmGMCSF 10 ng/mL (similar
results 10-25 ng/mL); and rmIL-4 10 ng/mL (similar results
10-25 ng/mL). Recombinant thrombopoietin, IL-3, and fibronectin were
also assessed, with negligible superimposed proliferative impacts (not
shown). BM cells were normally cultured for 6 to 7 days, harvested, and
washed twice in PBS before step 2 of culture.
In vitro BM differentiation/maturation (step 2 of culture)
Step 2 was initiated (0 hours) in CM, rmGMCSF, and optionally rmIL-4 in
24-well cluster plates, 4 million BM cells/well. DC1 polarization stimuli
such as CpG (ODN1826, 5 M) and lipopolysaccharide (LPS, 50 ng/mL)
were added between 18 to 24 hours, and cells harvested at 40 to 44 hours for
analyses. When included, rmIL-10, rmVEGF, rhTGF1, or PGE2 was
added between 0 to 24 hours of step 2 of culture. Alternatively, particulate
tumor cells, either viable unirradiated, viable irradiated (10 000 cGy), or
killed freeze-thawed lysate,28 were added. Viable tumor cells were some-
times labeled with CFSE (Molecular Probes, Eugene, OR) to allow
exclusion during fluorescence-activated cell sorting (FACS) analyses.21
FACS analyses of cultured BM
Cells were cultured in anti-CD32 mAb plus normal mouse IgG to block
FcR, then stained with fluorescently conjugated specific or isotype controls
mAbs (BD-PharMingen, Mountain View, CA).29 When additionally assess-
ing IL-12 production at the cellular level, the last 16 hours of step 2 of
culture were performed in monensin (Golgistop; BD-PharMingen). Then,
after FcR block and surface molecule staining, cells were treated with
CytoPerm/CytoFix (BD-PharMingen), then stained with PE anti–mouse
IL12p40 (BD-PharMingen) or PE isotype control.
Intracellular staining for TLR was performed directly on fixed, perme-
abilized cells with conjugated mAb (TLR3, TLR4, TLR8, TLR9), or
indirectly with unconjugated mAb (TLR7), and appropriate controls from
Imgenix (San Diego, CA). Staining for intracellular IRF4 and IRF8 was
performed with reagents from Santa Cruz Biotechnology (Santa Cruz, CA)
and mouse adsorbed F(ab)2 fragments of donkey anti–goat Ab (Research
Diagnostics, Concord, MA), following the method of Tamura et al.30
To isolate CD34pos and CD34neg cells from freshly harvested BM, the
latter were stained with FITC rat anti–mouse CD34 (dialyzed to remove
sodium azide), then sorted on a FACSAria (BD Biosciences, San Jose, CA),
yielding more than 96% pure CD34pos and CD34neg subpopulations.
In addition to PCR STAT determinations, pSTAT proteins were
analyzed on the cellular level by FACS.31 Nuclei of cultured BM cells were
permeabilized by sequential exposure to formalin (CytoFix) and 90%
methanol. Cells were then stained with PE- or FITC-conjugated
anti-pSTAT3 (pY705), anti-pSTAT5 (pY694), or isotype controls
(BD Biosciences).
Enzyme-linked immunosorbent assays
Supernatant contents of mIL12p70 heterodimer were quantified with
BD-PharMingen reagents. mIFN- and mIFN- were quantified with PBL
Biomedical Laboratories kits (New Brunswick, NJ).
T-cell cocultures
Prior to T-cell harvest, DCs were prepared under various step 1
conditions in CM; step 2 was performed in 1% non–heat-deactivated
mouse serum (MS) instead of FCS, during which BM cultures were
exposed to viable irradiated tumor cells, then CpG plus LPS. On the day
of DC harvest, T cells were freshly harvested from tumor-draining
lymph nodes (TDLNs) of 12-day tumor-bearing mice. The L-selectinlow
(tolerized pre-effector) fraction of T cells was isolated as previously
described,29,32 and cultured in CM-MS with immobilized anti-CD329,32
or variously conditioned DCs. Beginning on day 2 of T-cell culture,
some groups also received rhIL-2 (24 IU/mL), or rhIL-2, rhIL-7
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(50 ng/mL), and rhIL-15 (5 ng/mL). T cells were harvested for assays
and adoptive therapy after 12 days of culture.
T-cell specificity assays (intracellular IFN-)
Cultured T cells were replated in fresh CM-MS at 2 million T cells/well in
24-well plates. Whole-cell irradiated tumor digests (5000 cGy) were added
at 2 million cells/well as stimulators. Coculture proceeded for 18 hours,
with monensin added the final 13 hours. At harvest, individual treatment
groups were FcR blocked, then stained with FITC anti-CD4 and cychrome
anti-CD8. Following fixation/permeabilization, cells were additionally
stained with PE antimouse IFN- or isotype controls, then analyzed.
Adoptive immunotherapy
Viable tumor cells (1.5 million) were injected into healthy syngeneic mice
to establish intradermal tumors.29 Five or 10 days later, mice received
conventional nonmyeloablative whole-body irradiation (WBI, 500 cGy),29
followed by culture-activated T cells intravenously. Perpendicular bidimen-
sional tumor measurements were performed twice weekly. Mice were killed
when bidimensional product exceeded 225 mm2.
In vivo monitoring of BM cells
Cultured BM cells were labeled with CFSE21 and injected intravenously
into syngeneic mice bearing 10-day subcutaneous MCA-203 or MCA-105
tumors. Forty-eight hours later, mice were killed and tumors harvested and
enzymatically digested to produce whole-cell digests, with spleen cell
suspensions prepared in parallel.21 Preparations from individual mice were
analyzed by FACS for CFSEpos cell frequencies. Groups were then
costained with PE-conjugated mAb against DC-associated surface determi-
nants, and FACS gated to analyze the CFSEpos subpopulation.
Statistics
Survival among treatment groups was compared by Fisher exact test.
Individual mice were scored for final treatment outcome (lethal tumor vs
cure) and treatment groups compared. A 2-tailed P value less than .05
was deemed significant. Proliferative synergy was assessed by Wilcoxon
signed rank test for paired data (proliferation following exposure to
combined factors vs summed synchronous proliferations of the indi-
vidual factors). Trafficking accumulation of CFSE-labeled cells and
FACS pSTAT quantitations for cultured BM were assessed by Wilcoxon
signed rank test for paired data. In all cases, a 2-tailed P value less than
.05 was deemed significant.
Results
Later potentials for DC differentiation, DC maturation, and DC1
polarization are determined by early CD34pos cell conditioning
We cultured fresh mouse BM in 2 steps, a 6- to 7-day proliferative
culture (step 1) and a 48- to 72-hour postproliferative culture (step
2), followed in some experiments by T-cell coculture (Figure 1A).
Consistent with previous reports,18-20 3 treatment pairings
(Flt3L  IL-6, SCF  IL-6, or Flt3L  GMCSF) produced syner-
gistic proliferation during step 1 of culture (Figure 1B). Such
expansions represented a selective 35- to 80-fold numeric expan-
sion of the CD34pos cell subpopulation, with rapid dropout of
initially CD34neg cells (Figure 1C). CD34pos cells continued brisk
expansion for at least 1 additional week in culture if replenished
with the same treatment pairings (not shown).
Even though Flt3L is myeloproliferative when administered to
animals,5,33 step 1 of culture with single-agent Flt3L produced poor
yields, even when dosing extended up to 300 ng/mL (Figure 1B
and not shown). This validated previous reports that single-agent
Flt3L is poorly proliferogenic ex vivo unless BM cultures are
seeded at sufficiently high density to confer natural IL-6
supplementation.34
Prior to initial culture, freshly harvested CD34pos BM cells rarely
displayed DC or other lineage markers (not shown). By the end of step 1,
however, cultures treated with either single-agent Flt3L or single-agent
GMCSF displayed frequent differentiation into immature DCs, based on
their dual positivity for CD11c and MHC class II and low expression of
CD40 and B7.2 (Figure 1D; also see Figure S1A for full tested panel,
available on the Blood website; see the Supplemental Materials link at the
top of the online article). Conventional DCs (positive for CD11bpos but
negative for B220neg) predominated in both instances (Figure S1B).
Uniformly high MHC class II expression was a hallmark of Flt3L-
induced DC differentiation, whereas GMCSF-induced DCs were hetero-
geneous and predominantly low in regard to MHC class II expression
(Figure 1D).
Since Flt3L by itself was poorly proliferogenic (Figure 1B), we
examined the superimposed impacts of IL-6 or GMCSF, since
either agent produced proliferative synergy in conjunction
with Flt3L (Figure 1B). BM proliferatively conditioned with
Flt3L  IL-6 failed to acquire either CD11c or MHC class II
expression, due to a pronounced antidifferentiative effect attribut-
able to IL-6 (Figure 1D). In contrast, BM conditioned with either
Flt3L  GMCSF or Flt3L  IL-6  GMCSF developed heteroge-
neous differentiation that closely resembled treatment with GMCSF
alone (Figure 1D). Therefore, even though IL-6 could exert a
pronounced antidifferentiative effort upon Flt3L cultures, GMCSF
could dominantly antagonize the conditioning impacts of both
Flt3L and IL-6 during step 1 of culture.
Following step 1 conditioning, step 2 cultures were exposed to
TLR agonists to examine their real-time potentials for DC1
polarization (Figure 1E).6,7 Since both TLR9 and TLR4 were
invariably expressed at the end of step 1 mouse BM cultures (not
shown), we standardly used CpG (ODN 1826) and lipopolysaccha-
ride (LPS) during step 2 of culture to elicit coordinate activation of
MyD88 and TRIF pathways.6,7
Step 1 conditioning with single-agent GMCSF rendered a large
proportion of cells hyporesponsive or unresponsive to subsequent
TLR agonists, as evidenced by limited or absent up-regulation of
MHC class II, CD40, and B7.2 expression (Figure 1E; Figure
S2A). Gr-1 coexpression was a common feature of poorly respon-
sive subpopulation(s) (Figure S2B).35,36
In contrast, step 1 conditioning with single-agent Flt3L licensed
consistently high TLR responsiveness, manifested by nearly global
phenotypic DC maturation and only scant Gr-1pos elements during
subsequent step 2 of culture (Figure 1E; Figure S2B). However,
Flt3L’s global licensing impacts were antagonized if GMCSF was
also included during step 1 of culture (Figure 1E; Figure S2A).
Such inhibition was not observed if initial exposure to GMCSF was
deferred until step 2 of culture (not shown).
In contrast to GMCSF, IL-6 not only produced proliferative synergy in
conjunction with Flt3L (Figure 1B,C), but also promoted Flt3L’s global
licensing impacts.Although an undifferentiated state persisted during step
1 conditioning in Flt3L  IL-6 (Figure 1D), nearly the entire expanded
CD34pos progenitor cell pool responded to subsequent TLR stimulation
with DC differentiation, robust phenotypic maturation, and nearly uniform
IL-12 production (Figures 1E; S2A). IFN- was coelicited rather than
IFN- by all tested TLR agonist combinations, indicating that conven-
tional DC differentiation dominated during step 2 of culture (Figure
S2C).7 However, as for Flt3L, Flt3L  IL-6’s global licensing impacts
were abrogated if GMCSF was also included during step 1 of culture
(Figure 1E; Figure S2A).
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Figure 1. Numeric expansion and differentiation following exposure of bone marrow (BM) to various factors. (A) Schematic of test culture system. (B) BM freshly
harvested from C57BL/6 mice was cultured for 6 days (step 1 culture) in the specified factors (dosing in “Methods”), then counted. Each bar represents averaged 3 to
11 determinations plus or minus SD, each performed in synchronous comparison to at least five other groups. Asterisked bars indicate treatment combinations that displayed
significant proliferative synergy (see “Methods”). (C) Fresh uncultured mouse BM cell suspensions were mAb-stained and FACS sorted to separate CD34 and CD34
subpopulations. CD34 cells initially represented 10.8% (7%) of the total BM cells. The following groups were then subjected to 6-day step 1 culture either in Flt3L  SCF
plus IL-6 (striped bars) or in Flt3L  IL-6 (solid bars): unfractionated BM (12-15 million per flask); FACS sorted CD34 cells (12-15 million per flask); FACS-sorted CD34 cells
(2-3 million per flask); or FACS-sorted, unirradiated CD34 cells plus irradiated (3000 cGy) CD34 cells. Labels above bars indicate fold numeric expansion during the 6-day
culture. All numeric expansion observed was attributable to proliferation of the CD34 subpopulation, with no CD34 feeder layer requirement. (N.T. indicates condition not
tested). (D) Surface expression profiles at end of 6-day step 1 culture in various conditioning treatments. Individual treatments are listed in far left column. Ten different
treatments were synchronously compared (all groups shown in Figure S1A). Number within each histogram plot indicates the mean fluorescence specificity index for the
molecule tested, defined as the geomean fluorescent intensity of all cells after staining with the specified mAb (filled histogram), divided by the geomean background staining
intensity for isotype control mAb (unfilled histogram). Results shown are representative of three comprehensive comparisons. (E) Following the step 1 conditioning treatments
listed in far left column, each group was replated for step 2 in fresh medium with GMCSF plus IL-4 for 24 hours, followed by overnight exposure to paired TLR agonists (CpG
ODN 1826 and LPS). FACS analyses were then performed on day 2 of this step 2 culture. Ten different conditioning treatments were compared (selected groups shown in panel
E; all groups shown in Figure S2A). Far right column shows gross numeric expansion during initial step 1 culture. Number within each histogram is the calculated mean
fluorescence specificity index (see panel D). Representative of three comprehensive comparison experiments.
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The functional consequences of each of these conditioning regimens
proved age independent, with indistinguishable outcomes observed for
BM obtained from mice aged 4 to 80 weeks (not shown). Similar
responses were observed in all tested mouse strains.
Prior Flt3L or Flt3L  IL-6 conditioning promotes spontaneous
DC maturation and consistent TLR/IRF expression
Following lineage commitment, DCs typically remain immature
unless they are exposed to exogenous signals such as CD40
ligation, calcium ionophore, or TLR agonists.3,4,6-9 It was
observed, however, that BM cells conditioned in single-agent
Flt3L subsequently displayed spontaneous DC maturation, even
when GMCSF was the only exogenous supplement provided
during step 2 of culture (Figure 2B; Figure S3A). Similar
spontaneous DC maturation was also observed following step
1 proliferative conditioning in Flt3L  IL-6, even though the
inclusion of IL-6 had delayed the onset of DC differentiation
until the onset of step 2 of culture (Figure 1D vs Figure 2B;
Figure S3A). Spontaneous DC maturation following either
Flt3L or Flt3L  IL-6 conditioning was even more vigorous
when IL-4 was also provided during step 2 of culture (Figure
S3B). Marked up-regulation of the endocytic C-type lectin
receptor DEC-205 was a conspicuous component of such
spontaneous maturation (Figure S3C).
For all conditioning treatments other than Flt3L or
Flt3L  IL-6, spontaneous step 2 maturation was either highly
attenuated or not observed. Importantly, Flt3L  IL-6 was the
only factor pairing that resulted both in proliferative synergy
during step 1 of culture and in spontaneous DC maturation
during step 2 of culture (Figure 2B; Figure S3). Even when other
conditioning treatments evoked limited elements of DC matura-
tion during step 1 of culture (Figure 1D; Figure S1A), such
elements spontaneously reverted during step 2 of culture unless
exogenous maturational stimuli such as TLR agonists were also
provided (Figures 1E vs 2B; full panels in Figures S2A vs S3).
Flt3L or Flt3L  IL-6’s capacity to license spontaneous DC
maturation was abrogated, however, if GMCSF was also
included during step 1 conditioning (Figure 2B; Figure S3).
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Figure 2. Stem cells conditioned in Flt3L  IL-6 are licensed for DC1-polarization, spontaneous maturation, and resistance to tumor-associated immunosuppres-
sive factors. (A) Production of IL-12 by Flt3L  IL-6–conditioned BM cells following step 2 exposure to CpG plus LPS. Culture was performed as in Figure 1D, comparing
outcomes with or without CpG plus LPS treatment. FACS dot plots show results of intracellular cytokine assays for IL12p40 production. Percentages shown in upper right
quadrants are those of total BM cells specifically staining dually positive for MHC class II and intracellular IL-12 at the end of culture. Numbers in far right column show ELISA
content of IL12p70 heterodimer from culture supernatants run in parallel without monensin. Data are representative of 8 experiments. (B) Step 2 culture as in Figure 1E, except
following step 1 conditioning each group was replated in fresh medium for 72 hours solely with rGMCSF (no IL-4 or TLR agonists), after which FACS analyses were performed
(selected groups shown in panel B; all groups shown in Figure S3a). Number within each histogram is the calculated mean fluorescence specificity index at 72 hours. Results
shown are representative of 3 comprehensive comparisons. A similar but even more pronounced pattern of spontaneous maturation was observed during 48 to 72 hours step 2
culture in GMCSF  IL-4 (Figure S3B). (C) Step 2 cultures performed as in Figure 1E except that tumor-associated immunosuppressive factors were also added at 0 hour as
listed in far left column. Data are representative of 3 experiments. (D) Same as in panel A, except listed immunosuppressive factors were added at 0 hour, 1 hour, 2 hours, or
4 hours of step 2 culture, with supernatants analyzed by ELISA in triplicate for IL12p70 content at 44 hours of step 2 culture. Error bars indicate SD. Data are representative of
3 experiments.
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We characterized expression elements of the conventional DCs
that dominated step 2 of culture following Flt3L  IL-6 condition-
ing. Expression of TLR3, TLR4, TLR7, TLR8, and TLR9 remained
uniformly detectable at all stages of culture, functionally confirmed
by these cells’ broad responsiveness to respective TLR agonists
(Figures S2C and S4A). Interferon-regulatory factors IRF4 and
IRF8 were dually expressed both by DC precursors and polarized
DC1 (Figure S4B), demonstrating a largely homogeneous se-
quence of differentiation, maturation, and polarization following
Flt3L  IL-6 conditioning.
Flt3L  IL-6–conditioned DC precursors are stimulated rather
than inhibited by tumor interactions
We investigated whether Flt3L  IL-6 proliferative conditioning li-
censed uniform responsiveness to DC1 polarization stimuli even in the
presence of putative immunosuppressive factors. We added factors at
doses that equaled and exceeded those reported to inhibit the maturation
of other DC preparations.14-17 IL-10 and VEGF exposure had negligible
impacts upon DC1 polarization, whereas TGF1 exposure paradoxi-
cally enhanced both phenotypic maturation and IL-12 secretion (Figure
2C,D). Only early PGE2 exposure detectably inhibited TLR agonist-
induced phenotypic DC maturation and IL-12 production (Figure
2C,D). Nonetheless, a large subpopulation of Flt3L  IL-6–conditioned
BM cells resisted PGE2 inhibition even at the beginning of step 2 of
culture (Figure 2C, note the bimodal B7.2 expression), and such
resistance became increasingly prevalent within hours of step 2 of
culture (Figure 2D; Figure S5).
We tested the impact of exposing DCs to voluminous tumor
burdens at 16 to 24 hours of step 2 of culture. To each well
containing 4 million preconditioned BM cells, we added either
4 million freeze-thawed (killed) tumor cells; 3 million irradiated
(10 000 cGy), trypan-excluding apoptotic tumor bodies; or
2 million unirradiated, actively proliferating tumor cells.
After step 1 of Flt3L  IL-6 conditioning, contact with any
of these tumor materials accelerated DC phenotypic maturation,
mimicking the stimulatory impact of exposure to a single TLR
agonist (Figure 3A).6,7 Combining such tumor exposure with
IFN- treatment induced IL12p70 production (Figure 3A),
mimicking the impact of combined exposure to IFN- plus a
single TLR agonist.4,7 When other step 1 conditioning condi-
tions were compared, activating effects of tumor were either
highly attenuated or completely absent (Figure 3A).
The capacity of Flt3L  IL-6–conditioned DCs to be activated
by tumor contact proved strain independent, occurring even for
BALB/c BM-derived DCs despite this strain’s Th2-biasing ten-
dency37 (not shown). All tested tumor lines stimulated DC matura-
tion after Flt3L  IL-6 conditioning, including MCA-205 and
MCA-203 sarcomas and B16 melanoma derived from C57BL/6N
mice, CT26 colon adenocarcinoma derived from BALB/c mice,
and 888mel from a melanoma patient, and was not attributable to
endotoxin content (not shown). Both freshly harvested whole-cell
tumor digests and established tumor lines proved stimulatory,
indicating that host stromal cells were unessential, and DC
maturation was stimulated whether tumor was syngeneic, alloge-
neic, or xenogeneic (not shown). Although fully killed lysate was
effective, viable tumor proved more effective. Sequestration of
tumor from Flt3L  IL-6–conditioned DC precursors by Transwell
membranes (Corning) abrogated the activating effects of tumor,
underscoring a requirement for direct contact; in contrast, phagocy-
tosis of latex beads did not accelerate maturation (not shown).
Flt3L  IL-6–conditioned DCs promote superior reversal of
tumor-induced T-cell tolerance
We examined the capacities of previously conditioned DCs to reverse
tolerance in T cells harvested from mice bearing advanced tumors.
L-selectinlow T cells from tumor-draining lymph nodes (TDLNs) are
naturally sensitized to the relevant tumor but are also tolerized,
consequent to the progressive upstream tumor burden.29 In vitro
exposure to anti-CD3, followed by IL-2 stimulation, can reverse
tolerance and numerically expand antitumor effector T cells.29 However,
such polyclonal stimulation causes CD8 T cells to overgrow CD4
T cells, and lacks the element of antigen presentation needed to
selectively promote the tumor-specific T-cell subset.29,32
Conditioned DC precursors were transferred to step 2 of culture,
exposed to viable irradiated tumor, optionally further activated
with CpG plus LPS, then cocultured with tolerized TDLN T cells
from mice bearing the relevant tumor. Flt3L  IL-6–conditioned
DCs efficiently reversed tolerance and stimulated robust T-cell
proliferation, even when exogenous cytokines such as IL-2 were
not added to coculture (Figures 3B and 4A). CpG plus LPS
treatment enhanced but was unessential for such efficacy (not
shown). In contrast, DCs prepared after other conditioning treat-
ments typically proved lethal to T cells, and toxicity could not be
prevented by exogenous IL-2, IL-15, and/or IL-7 (Figures 3B and
4A). Cocultures driven by Flt3L  IL-6–conditioned DCs dis-
played superior outgrowth of both CD4 and CD8 tumor-specific
T cells compared with anti-CD3 treatment (Figure 4Bi,ii), and were
highly potent when provided as adoptive therapy against early or
advanced established tumors (Figure 4C; Figure S6).
Flt3L  IL-6–conditioned CD34pos cells achieve spontaneous
intratumoral DC maturation in vivo
Following various step 1 culture treatments, BM cells were CFSE
labeled and administered to 10-day tumor-bearing mice.
Cells injected immediately after step 1 conditioning with
Flt3L  GMCSF or Flt3L  GMCSF  IL-6 displayed negligible
trafficking into either tumor or spleen. In contrast, Flt3L plus
IL-6–conditioned BM cells infiltrated both established tumors and
spleen, achieving essentially uniform DC differentiation at either
location (Figure 5A,B). Moreover, accelerated DC maturation was
observed following entry into tumor compared with spleen (Figure
5B), consistent with observed stimulatory impacts of tumor contact
in vitro during step 2 of culture (Figure 3A).
Flt3L- versus GMCSF-conditioned DC programming reflects
competing STAT3- versus STAT5-dependent events
Knockout studies have demonstrated that Flt3 ligation transitions
CD34pos common precursors into committed DC precursors via a
STAT3-dependent process, whereas GMCSF promotes STAT3-
independent myeloid differentiation.38 IL-6 signaling is known to
induce gp130-mediated STAT3 activation in CD34pos cells,39
whereas GMCSF induces more complex STAT modulations,
including STAT5 activation, at several stages of myeloid differen-
tiation.38,40,41 Because step 1 GMCSF consistently abrogated the
unique conditioning impacts of Flt3L or Flt3L  IL-6, we exam-
ined whether STAT modulations played a pivotal role in GMCSF’s
apparently dominant regulation.
Step 1 IL-6 in the absence of GMCSF produced sustained
activation of STAT3 but not STAT5, as evidenced by intranuclear
staining for pSTAT3 (pY705) and pSTAT5 (pY694) (Figure 6A
end step 1; Figure S7). In contrast, inclusion of GMCSF as a
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Figure 3. Impact of tumor on conditioned BM cells, and impact of tumor-pulsed DCs upon subsequent T-cell cocultures. (A) Following step 1 conditioning treatments
listed in far left column, each group was replated at 4 million cells/well in fresh medium with only GMCSF added at the beginning of step 2 culture. Twenty-four hours later,
individual wells were also exposed to 3 million viable irradiated MCA-205 tumor cells. FACS analyses of cells were performed at 44 hours (20 hours after addition of tumor).
Histograms display expression of MHC class II, CD40, and B7.2 for each conditioning treatment, with or without exposure to tumor. The far right column displays supernatant
content of IL12p70 heterodimer 20 hours after tumor exposure when rmIFN- was also added to culture. Supernatant IL12p70 content was below detection (	 31 pg/24 hr)
following exposure to either rmIFN- or to tumor alone (not shown). Data are representative of 3 full comparison experiments. (B) Photos of individual T-cell cultures after 6-day
coculture with tumor-pulsed DCs or with anti-CD3. Labels denote step 1 DC conditioning treatments; step 2 DC cultures were performed in rGMCSF  rIL-4, with irradiated
MCA-203 cells added at 24 hours and CpG  LPS added at 44 hours. Four hours later, DCs were harvested for coculture with L-selectinlow T cells freshly harvested from
MCA-203 tumor-bearing mice. T cells were cocultured with DCs at a 8:1 ratio or were activated with immobilized anti-CD3. Cocultures shown also received exogenous
IL-2  IL-7  IL-15. Data are representative of 3 full comparison experiments, using an Olympus IX50 inverted microscope, an Olympus CPlan 10
/0.25 PhC objective lens, a
Sony DSC-S85 Cybershot, and Adobe Photoshop (Adobe Systems, Mountain View, CA) for compilation.
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component of any step 1 regimen depressed STAT3 activation and
produced biphasic up-regulation of pSTAT5 (Figure 6A end step 1;
Figure S7). These distinctive pSTAT expression patterns modulated
again during step 2 of culture, however, when cultures previously
conditioned in Flt3L  IL-6 now displayed the greatest capacity
for STAT5 activation (Figure 6A end step 2).
We next examined how STAT knockout BM preparations
responded to Flt3L  IL-6 conditioning. Consistent with STAT3’s
putative obligate role in Flt3L-induced DC differentiation,38 we
observed that STAT3KO BM could not survive Flt3L  IL-6 in
vitro conditioning (not shown). In contrast, STAT5KO BM re-
sponded to Flt3L  IL-6 conditioning with intact robust prolifera-
tion (not shown) and nearly uniform DC differentiation during
subsequent step 2 of culture (Figure 6B row 2). Nonetheless,
compared with wild-type littermates, Flt3L  IL-6–conditioned
STAT5KO DCs displayed submaximal DC maturation and IL12p70
production (Figure 6B row 2 vs row 1 and Figure 6D left).
Therefore, the proliferative and differentiative impacts of
Flt3L  IL-6 conditioning were absolutely STAT3-dependent,
whereas subsequent phenotypic maturation and DC1 polarization
were at least partially STAT5-dependent.
We also examined how STATKO BM preparations responded
to GMCSF-containing step 1 regimens (GMCSF alone,
Flt3L  GMCSF, or Flt3L  GMCSF  IL-6). All of these
GMCSF-based conditioning regimens were strikingly ineffective
for generating DCs from STAT5KO BM, instead yielding predomi-
nantly Gr-1pos, MHC class IIneg cells that displayed morphologic
features of mature neutrophils (eg, Figure 6B row 4, and data not
shown). In contrast, STAT3KO BM displayed normal proliferative
kinetics (not shown) and typical heterogeneous differentiation,
including DC differentiation, in response to all GMCSF-based
regimens (Figure 6C row 4). Following GMCSF-based condition-
ing, however, STAT3KO DCs displayed an abnormally heightened
maturational and IL12p70 response to TLR stimulation (Figure 6C
row 4 vs row 3 and Figure 6D right). Therefore, all tested
GMCSF-containing regimens required intact STAT5 for DC differ-
entiation, and later phenotypic maturation and DC1 polarization
displayed the capacity for negative regulation through STAT3.
Figure 4. Impacts of initial step 1 DC conditioning treatments upon subsequent culture of T cells from tumor-bearing mice. Tumor-pulsed DC preparations and
co-cultures were performed as in Figure 3B. (A) T-cell fold-expansion 12 days after initial exposure to tumor-pulsed DCs or to anti-CD3; labels indicate prior DC conditioning
treatments. As distinguished in the legend, the displayed T-cell expansions were performed either with no added cytokine, added rIL-2 only (24 IU/mL beginning day 2 of T-cell
culture), or IL-2  IL-7  IL-15 (50 ng IL-7, 5 ng IL-15). Data are representative of 3 experiments. (B) Coculture of T cells from tumor-bearing mice with Flt3L  IL-6–
conditioned DCs results in superior expansion of tumor-specific T cells. Step 1 DC conditioning was performed with Flt3L  IL-6, rest of DC preparation and T-cell cocultures as
in Figure 3B. After a 12-day coculture, T cells were harvested and replated either alone or with irradiated MCA-203 or MCA-105 as stimulator cells. Monensin
(Golgistop) was added after 5 hours, and cells analyzed after an additional 12 hours for intracellular IFN production. Dot plots show T cells recultured after expansion in
IL-2  IL-7  IL-15, but coculture with tumor pulsed, Flt3L  IL-6–conditioned DCs yielded virtually identical tumor-specificity even when no cytokines were added during the
12-day coculture (not shown). (Bi) Dot plots display CD4 versus IFN staining; the percentages shown in each dot plot is that of total CD4 cells producing IFN. (Bii) Dot plots
display CD8 versus IFN staining; the percentages in each dotplot is that of total CD8 cells producing IFN. This is representative of 6 experiments. (C) T cells driven with
Flt3L  IL-6–conditioned DCs are highly effective as adoptive therapy. Five-day established MCA-203 subcutaneous tumors were treated intravenously with T cells from
MCA-203 bearers after 12-day culture driven by Flt3L  IL-6–conditioned, tumor-pulsed DCs or by anti-CD3. Conventional nonmyelablative total body irradiation (500 cGy)
was given as an adjunct prior to T cells. Cure rates were 0/5 (A, No treatment); 2/5 (B, 5 million anti-CD3 driven T cells); 5/5 (C, 5 million Flt3L  IL-6 DC-driven T cells); 5/5
(D, same as C but 2 million T cells). Treatment outcome A versus C/D, P 	 .008; A versus B, P 	 .141; B versus C/D, P  .04. T-cell cultures driven by
Flt3L  IL-6–conditioned DCs were also highly effective against more advanced tumors (Figure S6). Data are representative of 4 experiments. Error bars represent SD.








Certain timely stimuli can condition DCs to adhere to an extended
period of programming. For example, we recently reported that
exposure of monocyte-derived human DCs to IFN  LPS not
only stimulated an initial burst of IL12p70 secretion, but also
licensed a second burst of IL12p70 secretion even days later if
CD40 ligation was experienced.6
We report here that durable DC programming can also be
secured at remarkably early stages of hematopoiesis, even prior
to discernible phenotypic DC lineage commitment. Exposure of
fresh mouse BM to Flt3L  IL-6 triggered multilog expansion
of CD34pos progenitor cells, and committed nearly all cells to
subsequent DC differentiation. Such programming included
subsequent spontaneous up-regulation of MHC/costimulatory
molecules, as well as nearly uniform responsiveness to DC1
polarization stimuli. Moreover, proliferative conditioning with
Flt3L  IL-6 conferred progressive resistance to many tumor-
associated immunosuppressive factors, as well as the capacity to
respond to either tumor contact or to TGF with facilitated DC1
polarization.
Flt3L  IL-6 treatment produced identical licensing whether per-
formed upon unfractionated BM or upon sorted CD34pos cells, indicat-
ing that more primitive (CD34neg/Sca-1pos) hematopoietic stem cells
were not essential conditioning targets. Pronounced biasing toward
ultimate DC differentiation was observed whether step 1 conditioning
was performed in Flt3L  IL-6 or Flt3L alone. However, in the absence
of coconditioning by IL-6, Flt3L-induced DC precursors remained scant
in number and displayed early maturation, whereas the inclusion of IL-6
produced an immense proliferative pool of CD11cneg/MHC class IIneg
cells that were nonetheless already committed to subsequent DC
differentiation. Such still phenotypically undifferentiated cells displayed
the capacity both for wide distribution following intravenous injection
and for spontaneous DC differentiation/maturation after entry into
tumor.
IL-6 and its receptor transducing component gp130 have long been
recognized to synergize for stem cell proliferation with receptor tyrosine
kinase–activating stimuli, including both c-kit ligand (SCF) and
Flt3-L,18-20 but only combined Flt3L  IL-6 also preconditioned for
nearly global differentiation of expanded CD34pos cells into spontane-
ously maturing DCs. Paradoxically, although GMCSF also synergized
with Flt3L to induce step 1 stem cell proliferation, GMCSF antagonized
every DC-licensing effect attributable to Flt3L.
Our evidence supports the existence of at least 2 discrete
pathways for conventional DC differentiation with strikingly
divergent functional outcomes, a Flt3L-promoted STAT3-
dependent pathway and a GMCSF-promoted STAT5-dependent
pathway (schematized in Figure 7). The Flt3L-promoted path-
way was highly potentiated by IL-6, most likely due to the
latter’s capacity to confer sustained STAT3 activation during
extended CD34pos cell proliferation, and biased for differentia-
tion into DC precursors that were uniformly facilitated for DC1
polarization, spontaneous DC maturation, and activation by
tumor contact. In contrast, the GMCSF-promoted, STAT5-
dependent pathway gave rise to diverse myeloid elements,
including DCs that failed to mature in the absence of further
downstream driving signals such as TLR agonists.
We hypothesize that STAT5-dependent DC differentiation
constitutes the normally dominant pathway, based on several
observations: (1) the inclusion of GMCSF during CD34pos
progenitor cell proliferation blocked STAT3 activation and
promoted STAT5-dependent myeloid differentiation regardless
of whether Flt3L or Flt3L  IL-6 were also present; (2) recent
studies indicate that STAT3-dependent DC differentiation is not
normally detectable in adult mice.42 Nonetheless, we have
observed that BM even from much older mice remains highly
responsive to exogenous Flt3L or Flt3L  IL-6 conditioning
(not shown). STAT3-dependent preempting of normal hemato-
poiesis in favor of dedicated DC production may therefore
reflect a reserved host response, perhaps to life-threatening
infection of the BM itself. Consistent with this possibility, Flt3L
and IL-6 are strongly induced by myelosuppression and BM
inflammation, respectively.43,44
Despite the competing roles played by STAT3 and STAT5 in
DC differentiation, it is also apparent that their respective
impacts change before and after DC differentiation occurs.
Pronounced sequential STAT3/STAT5 activation (ie, Flt3L  IL-
6–conditioned DCs in Figure 6A) corresponded to the greatest
observed attainment of DC tumor competence, and neither
STAT3 nor STAT5 knockout BM responded optimally to
Flt3L  IL-6 conditioning. The preemptive impacts of GM-CSF
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Figure 5. In vivo fate of BM cells administered
following step 1 conditioning treatments. Eighteen
million BM cells were labelled with CFSE and given by tail
vein to mice bearing 10-day MCA-203 subcutaneous
tumors. Forty-eight hours later, mice were euthanized
and single cell suspensions of tumors and spleens
processed for FACS analyses. (A) Frequency of CFSE
cells recovered in tumor or spleen. Each bar shows
average of 5 synchronously analyzed tumors or spleens
( SD) in a single experiment for each step 1 condition or
for background staining (no cells given). Flt3L  IL-6
versus Flt3L  GMCSF or Flt3L  IL-6  GMCSF condi-
tioning, P 	 .001. (B) Phenotype of CFSE cells re-
covered in tumor or spleen following in vitro
Flt3L  IL-6 conditioning. Numbers in parentheses in
each histogram display mean fluorescence specificity
indices. Results in panels A and B are representative of 3
separate experiments.
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during step 1 of culture appear to be mediated through early
combined STAT3 inhibition and STAT5 activation (Figure 6).
Paradoxically, however, appropriately delayed exposure to
GMCSF may promote maximal DC1 polarization through the
identical STAT modulations (Figure 7).
The mechanism(s) causing Flt3L  IL-6 preconditioned DCs
to respond to tumor as a maturational signal remains to be
elucidated. A plausible mechanism involves DC activation via
enhanced expression of lectin receptors such as asialoglycopro-
tein receptor and DEC-205 (Figure S3C),3,45 since identical or
similar carbohydrate receptors are used by tumoricidal macro-
phages to bind and kill tumor cells in an MHC-unrestricted and
antigen-unrestricted manner.46,47 Many tumor cells bind lectin
more avidly than nontransformed cells, due to a chronically high
density of exposed carbohydrates and a diminished presence
of differentiation elements that normally mask such car-
bohydrates.46,47 Similarly, we have observed that exposure to
albumin cross-linked with mannose or N-acetyl-glucosamine
accelerates the maturation of Flt3L  IL-6–conditioned BM
cells (not shown).
We are investigating why most proliferative conditioning
treatments caused DC preparations to be highly toxic to T-cell
cultures. Such lethality was unlikely attributable to activation of
regulatory T cells or indoleamine dioxygenase-expressing plas-
macytoid DCs (pDCs), since toxicity was not remedied by
adding exogenous IL-2 to the T-cell cocultures.48,49 There was,
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Figure 6. Impacts of STAT3 and STAT5 on BM conditioning. (A) Representative intracellular staining for pSTAT3 (pY705) versus pSTAT5 (pY694) following various
step 1 conditioning regimens, either at end of 6-day step 1 culture (left) or after an additional 48-hour step 2 culture in GMCSF  IL-4 (right). Numbers in parentheses in
each histogram display mean fluorescence specificity indices. Results are representative of 4 (left) and 3 (right) separate experiments, respectively. (B-D) Capacities of
STAT5 or STAT3 knockout mice to respond to various conditioning regimens. (B) BM was prepared from STAT5KO mice (St5 KO) or from littermates expressing wildtype
STAT5 (St5 LM) and subjected to step 1 conditioning with Ft3LIL-6 or Flt3LIL-6GMCSF. Results shown for Flt3LIL-6GMCSF are also highly representative of
GMCSF or Flt3LIL-6GMCSF conditioning outcomes (not shown). Proliferation kinetics during step 1 culture were comparable for KOs versus LMs (not shown).
Histograms display mean fluorescence specificity indices for DC maturation markers following 48 hours of step 2 culture in GMCSFIL-4, with CpGLPS added during
the final 18 hours. Results shown are representative of 3 experiments. (C) BM was prepared from STAT3KO mice (“St3 KO”) or from LMs expressing wild-type STAT3
(“St3 LM”) and subjected to step 1 conditioning and step 2 culture as in panel A. Results shown for Flt3LIL-6GMCSF are also highly representative of GMCSF or
Flt3LGMCSF conditioning. Proliferation kinetics during step 1 culture were comparable for KOs versus LMs, except that abject culture failure occurred when “St3 KO”
BM was conditioned with Flt3L IL-6 (not shown). Results shown are representative of 2 experiments. (D) ELISA comparisons of supernatants for IL12p70 at end of
step 2 cultures. BM was obtained from KO mice or from matched wildtype LMs, placed in standard step 1 cultures with Flt3LIL-6, Flt3LIL-6GMCSF, or GMCSF
alone as conditioning agents, and finally placed in 48-hour step 2 cultures with GMCSFIL-4, and CpGLPS added during the final 18 hours. Culture failure was
observed only when STAT3KO BM was conditioned with Flt3LIL-6. Data are presented as means plus or minus SD of 3 replicates and are representative of 3 (STAT5KO
vs LM) or 2 (STAT3KO vs LM) independently performed experiments.
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however, a correlation between the Gr-1pos cell–inducing ten-
dency of individual conditioning treatments and observed
lethality. It is therefore possible that the Gr-1pos subpopula-
tion(s) mediate the untoward effects of many of the conditioning
treatments.35,36 Consistent with this possibility, heightened
induction of Gr1pos myeloid suppressor cells appears to be the
basis of immune disruption by high GMCSF-producing vaccine
formulations.36 In contrast to GMCSF-conditioned cultures,
Flt3L  IL-6–conditioned DC cultures were exceptional for
their low Gr1pos content and consistent absence of toxicity, even
when added to T cells in high proportions.
The above experiments, as well as preliminary studies
with human CD34pos progenitor cells (not shown), demonstrate
that Flt3L  IL-6 may provide an effective means to proliferate,
condition, and mobilize highly therapeutic DC precursors
for tumor therapy. It has long been appreciated that
IL-6 has extremely potent therapeutic properties against estab-
lished mouse tumors, even when administered as a single
agent.50 We postulate that the major mechanistic role and
benefit of IL-6 therapy will be in tandem with Flt3L to
proliferate and condition tumor-competent DC precursor popu-
lations in cancer patients.
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